Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2401861
Max Phase: Preclinical
Molecular Formula: C26H21F3N4OS
Molecular Weight: 494.54
Molecule Type: Small molecule
Associated Items:
ID: ALA2401861
Max Phase: Preclinical
Molecular Formula: C26H21F3N4OS
Molecular Weight: 494.54
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)c1ccccc1Oc1ncccc1Nc1nc(C(F)(F)F)c(-c2ccc(C#N)cc2)s1
Standard InChI: InChI=1S/C26H21F3N4OS/c1-25(2,3)18-7-4-5-9-20(18)34-23-19(8-6-14-31-23)32-24-33-22(26(27,28)29)21(35-24)17-12-10-16(15-30)11-13-17/h4-14H,1-3H3,(H,32,33)
Standard InChI Key: CHZZSTAXLDURKI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 494.54 | Molecular Weight (Monoisotopic): 494.1388 | AlogP: 7.93 | #Rotatable Bonds: 5 |
Polar Surface Area: 70.83 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 10.00 | CX Basic pKa: 2.22 | CX LogP: 7.94 | CX LogD: 7.94 |
Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.31 | Np Likeness Score: -1.61 |
1. Pi Z, Sutton J, Lloyd J, Hua J, Price L, Wu Q, Chang M, Zheng J, Rehfuss R, Huang CS, Wexler RR, Lam PY.. (2013) 2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents., 23 (14): [PMID:23743287] [10.1016/j.bmcl.2013.05.025] |
2. Hossain N, Ivanova S, Timén ÅS, Bergare J, Mussie T, Bergström L.. (2013) Design, synthesis and structure-activity relationships of zwitterionic spirocyclic compounds as potent CCR1 antagonists., 23 (14): [PMID:23769642] [10.1016/j.bmcl.2013.05.087] |
Source(1):